Decisions and risk

How a web of answered, connected questions helps you judge a company after an FDA letter: six signals, a checklist, and what the record cannot tell you.

After an FDA Complete Response Letter, the decisions that follow are expensive: whether to invest, whether to partner, how to plan a resubmission, what to report. They are usually made from the company's press release and a few analyst notes. Deep research offers something different: the regulator's own words beside the company's, every concern traced across letters, and every answer checkable in minutes.

This page describes how to use that for decisions and risk. It is a way of reading the record, not a forecast.

Six signals in a question web#

1. A gap between the letter and the filing: Compare What did the letter object to? with How did the company describe it? A difference is disclosure risk to be understood: what investors were told, against what the regulator wrote. Verrica's 2020 announcement said “No Clinical Safety or Efficacy Issues Identified”; the letter said the FDA remained concerned that the product “is not safe for use by HCPs”.
2. An omission, confirmed by search: A dotted “not in” node marks something the letter raised and the filing does not mention, with the search terms that prove it. Ask why, and whether a later filing filled the gap.
3. A concern that carries over: What changed between the letters? shows which concerns survived a resubmission. A concern that appears in two letters (Aldeyra's request for another adequate and well-controlled study, the facility named in both of CorMedix's) is one the company's response did not resolve the first time. It is the first thing to check in the next one.
4. A load-bearing question: On the web, a question with many connections rests on passages that many other answers also use. Those passages carry the history. If one of them turns out differently (a trial result, a facility inspection) many answers change at once. On Replimune's web, the confirmatory Phase 3 trial connects five questions, from the first letter to what remains unresolved after approval.
5. Two accounts of one event: When the FDA and the company describe the same meeting or advice differently, both are quoted. A sustained disagreement (Was the FDA's advice to Replimune consistent?) is a regulatory relationship risk, and it is often where formal dispute resolution begins.
6. A path other cases have taken: The cross-case view places a company's current step among the paths other companies took from the same kind of letter. It does not predict the outcome, but it tells you what the next steps usually are, and what other companies needed to get through them.

A working checklist#

For a company with a question web, or a concept-preview page on /ask:

Read the letter's own objections. Open What did the FDA's letter object to? and read the passages quoted, not just the short answer. Note whether the deficiencies are about efficacy, safety, manufacturing or labelling.
Read the company's account beside it. Open How did the company describe the letter? List what matches, what differs and what is missing.
Check what carried over. If there is more than one letter, open What changed between the letters? Mark every concern that appears twice.
Find the load-bearing questions. On the web, look for the questions with the most connections and hover them. Note the shared passages: they are what the outcome depends on.
Read What remains unresolved? It lists what the record cannot yet answer: a trial not yet read out, a document not yet published.
Place the company among other cases. Compare its letter type and current step with the paths in What happens after a Complete Response Letter?
Verify what you will rely on. For every passage your decision rests on, follow Open at the source → and read it in the original. See Trace an answer to its source.

Risks the record shows#

Risk	Where it shows in deep research	Example
Regulatory	Carried-over concerns; the kind of deficiency; disagreement over advice	Aldeyra: the same request in the same words in 2023 and 2025
Disclosure	Gaps and omissions between letter and filing; drifting descriptions	Replimune's 8-K on the second letter does not mention the early Phase 3 analysis
Manufacturing	Facilities and suppliers named in letters; inspection outcomes	CorMedix: a heparin supplier's warning letter for another product became a condition
Clinical	Confirmatory trials; populations behind reported figures	RP1: three response rates for three populations; continued approval may depend on a confirmatory trial
Litigation	Class actions and derivative suits following letters	Verrica: a class action filed after the third letter; claims over May–June 2021 statements allowed to proceed
Execution	Job cuts, manufacturing changes, leadership changes after letters	Replimune: job cuts and a smaller manufacturing operation after the second letter

Why it helps decisions#

It is faster to check than to research. Each answer is already built from verified passages. A decision-maker's time goes on judgement, not on finding page 5 of a letter.
It shows the evidence, not a verdict. Where the record supports two readings, both are quoted. The decision stays with the reader, who can see exactly what it rests on.
It shows what is unknown. “Not in this record” is as useful for risk as any finding: it marks the questions only time, or a new document, will answer.
It accumulates. Every new case adds to the cross-case questions, so the context for the next decision is richer than for the last.